TA
VRTX icon

TrueWealth Advisors’s Vertex Pharmaceuticals VRTX Stock Holding History

TrueWealth Advisors’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-1,223
Closed -$544K – 233
2025
Q2 		$544K Buy
1,223
+135
+12% +$62.2K 0.16% 118
2025
Q1 		$527K Buy
1,088
+51
+5% +$23.8K 0.17% 104
2024
Q4 		$418K Buy
1,037
+271
+35% +$126K 0.14% 138
2024
Q3 		$356K Buy
+766
New +$368K 0.12% 156

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

TrueWealth Advisors's VRTX Position: Q3 2025 in Review

TrueWealth Advisors sold out of Vertex Pharmaceuticals (VRTX) in Q3 2025, closing a stake of 1,223 shares — an estimated $544K sold.

TrueWealth Advisors first reported a position in VRTX in Q3 2024 and held it in 4 quarters. The position peaked at $544K in Q2 2025. 1,519 funds tracked by Wall St. Rank hold VRTX as of Q3 2025.

  • TrueWealth Advisors reported no remaining Vertex Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
  • TrueWealth Advisors sold 1,223 Vertex Pharmaceuticals shares in Q3 2025, an estimated $544K.
  • TrueWealth Advisors first reported a position in Vertex Pharmaceuticals in Q3 2024 and held it in 4 quarters.
  • TrueWealth Advisors's Vertex Pharmaceuticals position peaked at $544K in Q2 2025.
  • 1,519 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q3 2025.

Based on TrueWealth Advisors's 13F filing for Q3 2025, filed 15 Oct 2025.